Axovant needs a PR to explain that Oxford BioMedica MUST dedicate capacity to produce adenovirus vectors for the Astrazeneca AZD1222 vaccine for Covid 19 and the Novartis Kymriah® cancer gene therapy.
This is a priority over the Parkinson's gene therapy for the Axovant trial. The Axovant trial is very promising and is just delayed due to the covid 19 pandemic.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.